Dong-A ST is a company operating in the pharmaceutical industry.
Dong-A has been the largest pharmaceutical company in Korea since 1967. We have solidified our leading market position on the strength of in-house developed products such as Suganon tab. Evogliptin, the DPP-4 inhibitor for type 2 diabetes mellitus, Zydena tab. Udenafil, the fourth PDE5 inhibitor in the world for erectile dysfunction, Stillen tab. Eupatilin for herbal treatment of gastritis and Motilitone tab. Corydaline for functional dyspepsia. Furthermore, we are offering branded generic drugs (anti-cancer, anti-TB, etc.
Company type
Products and services
Biopharmaceuticals, APIs (Active Pharmaceutical Ingredients)
Markets
Oceania, North America (USA, Canada), Middle East Region (e.g. UAE), Central America (e.g. Mexico), East Asia (e.g. China, Japan, Korea), Europe – EU countries, Europe – non EU (e.g. UK, Russia, ex-CIS countries), South America (e.g. Brazil, Colombia), South Asia (e.g. India, Pakistan, Sri Lanka), South East Asia (e.g. Thailand, Philippines, Singapore)
Address
Dong-A ST, 64, CHEONHO-DAERO,, DONGDAEMUN-GU, SEOUL, Korea, Republic of, 130-708
